Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Loading...

References

  1. Michelle M Kittleson. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.. Journal of the American College of Cardiology, 2025
  2. Thibaud Damy. Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage.. European journal of heart failure, 2025
  3. Daniel P Judge. Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.. Journal of the American College of Cardiology, 2025
  4. Mathew S Maurer. Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B.. Journal of the American College of Cardiology, 2025
  5. Pablo Garcia-Pavia. Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association.. European heart journal, 2025
  6. Pablo García-Pavía. Monitoring Disease Progression in Patients With Transthyretin Amyloid Cardiomyopathy.. JACC. Heart failure, 2025
  7. Julian D Gillmore. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.. The New England journal of medicine, 2024
  8. C. Nitsche. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis.. European journal of heart failure, 2024
  9. Michelle M Kittleson. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee.. Journal of the American College of Cardiology, 2023
  10. A. Ioannou. Conventional heart failure therapy in cardiac ATTR amyloidosis. European Heart Journal, 2023
  11. A. Ioannou. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. Circulation, 2022
  12. P. García-Pavía. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021
  13. J. Gillmore. A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018
  14. M. Maurer. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. The New England Journal of Medicine, 2018